The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Bruno PaivaDuring the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub spoke to Bruno Paiva, University of Navarra, Pamplona, ES. We asked, Why could mass spectrometry substitute immunofixation electrophoresis (IFE) in diagnosis and monitoring of MM?
Why could mass spectrometry substitute IFE in diagnosis and monitoring of MM?
Paiva describes the benefits of mass spectrometry over IFE, including improved sensitivity, specificity, and prevention of monoclonal antibody interference. He then analyzes the potential for synergy across different imaging techniques when predicting and measuring patient outcomes.